Oküler Yüzey Skuamöz Neoplaziler
Referanslar
Lee GA, Hirst LW. Ocular surface squamous neoplasia. Surv Ophthalmol. 1995;39(6):429–450. https://doi.org/10.1016/S0039-6257(05)80054-2
Shields CL, Shields JA. Tumors of the conjunctiva and cornea. Surv Ophthalmol. 2004;49:3–24
Basti S, Macsai MS. Ocular surface squamous neoplasia: a review. Cornea. 2003;22:687–704.
Hollhumer R, Williams S, Michelow P Ocular surface squamous neoplasia: Population demographics, pathogenesis and risk factors. Afr. Vis. Eye Health. 2020; 79. Available at: http://www.avehjourna l.org/index.php/AVEH/article/view/553 [Accessed June 23, 2020]
Shields CL, Chien JL, Surakiatchanukul T, et al. Conjunctival tumors: Review of clinical features, risks, biomarkers, and outcomes – The 2017 J. Donald M. Gass Lecture. Asia Pac J Ophthalmol. 2017;6(2):109–120. https://doi.org/10.22608/APO.201710
Gichuhi S, Sagoo MS, Weiss HA, et al. Epidemiology of ocular surface squamous neoplasia in Africa. Trop Med Int Health. 2013;18(12):1424–1443. https://doi.org/10.1111/tmi.12203
Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: A pooled analysis. Lancet. 2005;366(9490):991–998.
Gichuhi S, Ohnuma S, Sagoo MS, et al. Pathophysiology of ocular surface squamous neoplasia. Exp Eye Res. 2014;129:172–182. https://doi.org/10.1016/j.exer.2014.10.015
Baeten JM, McClelland RS, Richardson BA, et al. Vitamin A deficiency and the acute phase response among HIV-1-infected and -uninfected women in Kenya. J Acquir Immune Defic Syndr. 2002;31:243–249. https://doi.org/10.1097/00126334-200210010-00016
Pe’er J. Ocular Surface Squamous Neoplasia. Ophthalmol Clin N Am 18 (2005) 1 – 13.
Honavar S, Manjandavida F. Tumors of the ocular surface: A review. Indian J Ophthalmol. 2015;63(3):187. https://doi.org/10.4103/0301-4738.156912
McKelvie PA. Squamous cell carcinoma of the conjunctiva: A series of 26 cases. Br J Ophthalmol. 2002;86(2):168–173. https://doi.org/10.1136/bjo.86.2.168
Amin MB, Edge SB, Greene FL, et al., editors. AJCC cancer staging manual. Cham: Springer; 2017. https://doi.org/10.1007/978-3-319-40618-3
Venkateswaran N, Sripawadkul W, Karp CL. The role of imaging technologies for ocular surface tumors. Curr Opin Ophthalmol. 2021 Jul 1;32(4):369-378.
Ersoz C, Yagmur M, Ersoz TR, Yalaz M. Preoperative brush and impression cytology in ocular surface squamous neoplasms. Acta Cytol 2003;47(1): 13 – 5
Karp CL, Mercado C, Venkateswaran N, Ruggeri M, Galor A, Garcia A, et al. Use of high-resolution optical coherence tomography in the surgical management of ocular surface squamous neoplasia: a pilot study. Am J Ophthalmol. 2019;206:17–31
Cicinelli MV, Marchese A, Bandello F, Modorati G. Clinical management of ocular surface squamous neoplasia: a review of the current evidence. Ophthalmol Ther. 2018;7:247–62.
Santoni A, Thariat J, Maschi C, Herault J, Baillif S, Lassalle S, et al. Management of invasive squamous cell carcinomas of the conjunctiva. Am J Ophthalmol. 2019;200:1–9.
Kaliki S, Jajapuram SD, Maniar A, Taneja S, Mishra DK. Ocular surface squamous neoplasia with intraocular tumour extension: a study of 23 patients. Eye. 2020;34:319–26.
Nanji AA, Sayyad FE, Karp CL. Topical chemotherapy for ocular surface squamous neoplasia. Curr Opin Ophthalmol. 2013;24:336–42.
Al Bayyat G, Arreaza-Kaufman D, Venkateswaran N, Galor A, Karp CL. Update on pharmacotherapy for ocular surface squamous neoplasia. Eye Vis. 2019;6:24.
Ballalai PL, Erwenne CM, Martins MC, Lowen MS, Barros JN. Long-term results of topical mitomycin C 0.02% for primary and recurrent conjunctival-corneal intraepithelial neoplasia. Ophthal Plast Reconstr Surg. 2009;25:296–9.
Kusumesh R, Ambastha A, Kumar S, Sinha BP, Imam N. Retrospective comparative study of topical interferon α2b versus mitomycin C for primary ocular surface squamous neoplasia. Comp Study. 2017;36:5.
Russell HC, Chadha V, Lockington D, Kemp EG. Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications. Br J Ophthalmol. 2010;94:1316–21.
Zaki AA, Farid SF. Management of intraepithelial and invasive neoplasia of the cornea and conjunctiva: a long-term follow up. Cornea. 2009;28:986–8
Rudkin AK, Dempster L, Muecke JS. Management of diffuse ocular surface squamous neoplasia: efficacy and complications of topical chemotherapy: Management of diffuse ocular surface squamous neoplasia. Clin Exp Ophthalmol. 2015;43:20–25.
Abraham LM, Selva D, Casson R, Leibovitch I. The clinical applications of fluorouracil in ophthalmic practice. Drugs. 2007;67:237–55.
Parrozzani R, Frizziero L, Trainiti S, Testi I, Miglionico G, Pilotto E, et al. Topical 1% 5-fluoruracil as a sole treatment of corneoconjunctival ocular surface squamous neoplasia: long-term study. Br J Ophthalmol. 2017;101:1094–9.
Rudkin AK, Muecke JS. Adjuvant 5-fluorouracil in the treatment of localised ocular surface squamous neoplasia. Br J Ophthalmol. 2011;95:947–50. 59.
Lewczuk N, Zdebik A, Bogusławska J. Interferon Alpha 2a and 2b in Ophthalmology: A Review. J Interferon Cytokine Res. 2019;39:259–72.
Stannard C, Sauerwein W, Maree G, Lecuona K. Radiotherapy for ocular tumours. Eye. 2013;27:119–27.
Esmaeli B, Sagiv O. Targeted biological drugs and immune check point inhibitors for locally advanced or metastatic cancers of the conjunctiva, eyelid, and orbit. Int Ophthalmol Clin. 2019;59: 13–26.
